Literature DB >> 6150103

Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

P H Hinderling, O Schmidlin, J K Seydel.   

Abstract

The structure and pharmacokinetics relationship of 14-beta-adrenoceptor antagonists was investigated in humans. Statistically significant linear and parabolic correlations were found to exist between standard and derived mean pharmacokinetic parameters and the apparent octanol/buffer (pH 7.4) partition coefficient of the compounds. The lipophilic/hydrophilic properties were the primary determinants for the pharmacokinetic behavior of the compounds. Most of the pharmacokinetic parameters were also significantly correlated with the plasma protein/plasma water partition coefficient for the compounds. When the values of the pharmacokinetic parameters of the individual compounds were predicted from the regressions on the apparent partition coefficients in octanol/buffer (pH 7.4) and in plasma protein/plasma water, the error was on average 60%.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150103     DOI: 10.1007/BF01061721

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  47 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  The disposition of timolol in man.

Authors:  P Vermeij; M el-Sherbini-Schepers; P A van Zwieten
Journal:  J Pharm Pharmacol       Date:  1978-01       Impact factor: 3.765

3.  Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Authors:  G Alván; M Lind; B Mellström; C von Bahr
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

4.  Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine.

Authors:  E R Garrett; K Schnelle
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

5.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

6.  Practolol metabolism. II. Metabolism in human subjects.

Authors:  P R Reeves; D E Case; H T Jepson; D J McCormick; J T Nicholls; R H Felix; P J Holt; F J Zacharias; R W Fluke
Journal:  J Pharmacol Exp Ther       Date:  1978-05       Impact factor: 4.030

7.  Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.

Authors:  J K Seydel; D Trettin; H P Cordes; O Wassermann; M Malyusz
Journal:  J Med Chem       Date:  1980-06       Impact factor: 7.446

8.  Kinetics and absolute bioavailability of atenolol.

Authors:  W D Mason; N Winer; G Kochak; I Cohen; R Bell
Journal:  Clin Pharmacol Ther       Date:  1979-04       Impact factor: 6.875

9.  Measurement of hydrophobicity, surface activity, local anaesthesia, and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine -adrenergic blocking agents.

Authors:  D Hellenbrecht; B Lemmer; G Wiethold; H Grobecker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

10.  Pindolol availability in hypertensive patients with normal and impaired renal function.

Authors:  N P Chau; Y A Weiss; M E Safar; D E Lavene; D R Georges; P L Milliez
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

View more
  9 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

3.  Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Authors:  D Brockmeier; P Hajdù; W Henke; E Mutschler; D Palm; W Rupp; H Spahn; M T Verho; A Wellstein
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum.

Authors:  R W Wittendorf; J E Swagzdis; R Gifford; B A Mico
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

6.  Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships.

Authors:  Xinning Yang; Yash A Gandhi; David B Duignan; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-11       Impact factor: 4.009

7.  Pharmacokinetic parameters of bevantolol in volunteers.

Authors:  P Vermeij; P van Brummelen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.

Authors:  D H Pitkin; B A Mico; R D Sitrin; L J Nisbet
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

9.  Mechanistic approaches to volume of distribution predictions: understanding the processes.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.